[Hepatic failure and renal failure in antineoplastic chemotherapy, and its treatment].
Various degrees of hepatic failure and renal abnormality may occur as complications of anti-neoplastic chemotherapy. The etiologies of alterations in liver function and the clinical pictures of chemotherapeutic agents as potential hepatotoxins, and of drugs with hepatic metabolism, and their combination uses, are discussed. As strategies are available for prevention and amelioration of these problems, management by periodic reevaluation of liver function is most important. In renal failure, myeloma kidney as tumor-associated nephropathy, hyperuricemic nephropathy and treatment-related nephrotoxicity are discussed with regard to their etiologies and clinical pictures. Aggressive management with intravenous hydration can ameliorate these complications of therapy, and careful monitoring of renal function and serum electrolytes are essential during administration of these agents.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000517:prevention & control; D008099:Liver / Q000378:metabolism; D008107:Liver Diseases / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents